Literature DB >> 33651272

An elaborative NMR based plasma metabolomics study revealed metabolic derangements in patients with mild cognitive impairment: a study on north Indian population.

Umesh Kumar1, Abhai Kumar2, Smita Singh3, Payal Arya1, Sandeep Kumar Singh1,4, Rameshwar Nath Chaurasia5, Anup Singh3, Dinesh Kumar6.   

Abstract

Mild cognitive impairment (MCI) is transition phase between cognitive decline and dementia. The current study aims to investigate altered metabolic pattern in plasma of MCI for potential biomarkers. MCI (N = 50) and healthy controls (HC, N = 50) age group 55-75 years were screened based on Mini Mental State Examination Test (MMSE) and diffusion tensor imaging (DTI imaging). The MMSE score of MCI was significantly lower (25.74 ± 1.83) compared to healthy control subjects (29 ± 1). The MCI patients exhibit significant changes in white matter integrity in the right frontal lobe, right temporal lobe, left frontal lobe, forcep major, fornix, corpus callosum. Further, the plasma samples of twenty seven MCI patients (N = 27) and twenty HC subjects (N = 20; having no significant differences in any demographics) were analyzed using 1H NMR based metabolomics approach. Consistent with many previous reports, the levels of several plasma metabolites were found to be elevated in MCI patients compared to healthy controls. Further univariate and multivariate ROC curve analyses provided three plasma metabolites as a diagnostic panel of biomarker for MCI; which are lysine, glycine, and glutamine. Overall, the results of this study will help to improve the diagnostic and prognostic strategies of MCI in addition to improving our understanding about disease pathogenesis. We believe that the over-nutritional metabolic phenotype of MCI needs to be targeted for developing future dietary interventions so that the progression of MCI can be limited. Metabolic derangements associated with Mild Cognitive Impairment.

Entities:  

Keywords:  1H NMR; Alzheimer’s disease; Diffusion tensor imaging; Metabolomics; Mild cognitive impairment

Mesh:

Year:  2021        PMID: 33651272     DOI: 10.1007/s11011-021-00700-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  49 in total

Review 1.  Branched-chain amino acid enriched supplements as therapy for liver disease.

Authors:  Michael Charlton
Journal:  J Nutr       Date:  2006-01       Impact factor: 4.798

2.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

3.  Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry.

Authors:  Raúl González-Domínguez; Antonia García; Tamara García-Barrera; Coral Barbas; José Luis Gómez-Ariza
Journal:  Electrophoresis       Date:  2014-10-09       Impact factor: 3.535

4.  Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine.

Authors:  Gao-Shang Chai; Xia Jiang; Zhong-Fei Ni; Zhi-Wei Ma; Ao-Ji Xie; Xiang-Shu Cheng; Qun Wang; Jian-Zhi Wang; Gong-Ping Liu
Journal:  J Neurochem       Date:  2013-02       Impact factor: 5.372

Review 5.  Neurologic damage and neurocognitive dysfunction in urea cycle disorders.

Authors:  Gregory M Enns
Journal:  Semin Pediatr Neurol       Date:  2008-09       Impact factor: 1.636

6.  A UHPLC-TOF/MS method based metabonomic study of total ginsenosides effects on Alzheimer disease mouse model.

Authors:  Yingge Gong; Ying Liu; Ling Zhou; Xin Di; Wei Li; Qing Li; Kaishun Bi
Journal:  J Pharm Biomed Anal       Date:  2015-07-16       Impact factor: 3.935

7.  The paradox of overnutrition in aging and cognition.

Authors:  Roger A Fielding; John Gunstad; Deborah R Gustafson; Steven B Heymsfield; John G Kral; Lenore J Launer; Josef Penninger; David I W Phillips; Nikolaos Scarmeas
Journal:  Ann N Y Acad Sci       Date:  2013-05-17       Impact factor: 5.691

8.  Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects.

Authors:  Domenico Ciavardelli; Fabrizio Piras; Ada Consalvo; Claudia Rossi; Mirco Zucchelli; Carmine Di Ilio; Valerio Frazzini; Carlo Caltagirone; Gianfranco Spalletta; Stefano L Sensi
Journal:  Neurobiol Aging       Date:  2016-03-15       Impact factor: 4.673

9.  Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.

Authors:  Michael C Donohue; Setareh H Moghadam; Allyson D Roe; Chung-Kai Sun; Steven D Edland; Ronald G Thomas; Ronald C Petersen; Mary Sano; Douglas Galasko; Paul S Aisen; Robert A Rissman
Journal:  Alzheimers Dement       Date:  2014-10-07       Impact factor: 21.566

10.  MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.

Authors:  Jasmine Chong; Othman Soufan; Carin Li; Iurie Caraus; Shuzhao Li; Guillaume Bourque; David S Wishart; Jianguo Xia
Journal:  Nucleic Acids Res       Date:  2018-07-02       Impact factor: 16.971

View more
  4 in total

1.  Molecular investigations on Candida glabrata clinical isolates for pharmacological targeting.

Authors:  Hrishikesh Gupta; Payal Gupta; Manikyaprabhu Kairamkonda; Krishna Mohan Poluri
Journal:  RSC Adv       Date:  2022-06-14       Impact factor: 4.036

2.  Elevated Circulatory Proline to Glutamine Ratio (PQR) in Endometriosis and Its Potential as a Diagnostic Biomarker.

Authors:  Kusum Kusum; Ritu Raj; Sangeeta Rai; Pranjali Pranjali; Ashish Ashish; Sara Vicente-Muñoz; Radha Chaube; Dinesh Kumar
Journal:  ACS Omega       Date:  2022-04-19

3.  Serum Metabolic Disturbances in Lung Cancer Investigated through an Elaborative NMR-Based Serum Metabolomics Approach.

Authors:  Anjana Singh; Ved Prakash; Nikhil Gupta; Ashish Kumar; Ravi Kant; Dinesh Kumar
Journal:  ACS Omega       Date:  2022-01-31

4.  Nrf2/HO-1 Signaling Activator Acetyl-11-keto-beta Boswellic Acid (AKBA)-Mediated Neuroprotection in Methyl Mercury-Induced Experimental Model of ALS.

Authors:  Elizabeth Minj; Shubham Upadhayay; Sidharth Mehan
Journal:  Neurochem Res       Date:  2021-06-01       Impact factor: 3.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.